Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03536663 · ClinicalTrials.gov registry record · NA
Clinical Study to Assess the Performance of the Dialyzer With Endexo™
A NA study, sponsored by Fresenius Medical Care North America.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT03536663 is a NA study that has completed, run by Fresenius Medical Care North America. The registered enrollment target is 23 participants.
The verdict
NCT03536663, a NA study, has completed, sponsored by Fresenius Medical Care North America.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
Endexo™ is an additive that is blended into the fiber solution during manufacturing of the hemodialyzer hollow fibers. The intended purpose of the additive is to increase blood compatibility in the finished dialyzer, which is referred to as the "dialyzer with Endexo."
Interventions
- DEVICE Optiflux and Dialyzer with Endexo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-08-29 |
| Est. Completion | 2019-06-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03536663
The ClinicalTrials.gov registry entry for NCT03536663 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fresenius Medical Care North America, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Optiflux and Dialyzer with Endexo is the first listed.
NCT03536663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03536663 about?
NCT03536663 is a clinical study titled "Clinical Study to Assess the Performance of the Dialyzer With Endexo™". Endexo™ is an additive that is blended into the fiber solution during manufacturing of the hemodialyzer hollow fibers. The intended purpose of the additive is to increase blood compatibility in the finished dialyzer, which is referred to as the "dialyzer with Endexo."
What is the current status of trial NCT03536663?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2018-08-29. Estimated completion is 2019-06-17.
What interventions are being tested in trial NCT03536663?
The interventions under investigation include: Optiflux and Dialyzer with Endexo (DEVICE).
Who is sponsoring clinical trial NCT03536663?
This trial is sponsored by Fresenius Medical Care North America, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.